Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC.MIRA · Entity 7362 | Director | August 17, 2023 | August 21, 2023 |
| Telomir Pharmaceuticals, Inc.TELO · Entity 6962 | Director · General Counsel | February 08, 2024 | February 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MIRA PHARMACEUTICALS, INC.
Report date August 17, 2023 · Filed August 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.50 · Expires 2033-08-17 | Direct | 10,000 |
Reported balance
After 2023-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-17 · Grant · Acquired 10,000 · Balance 10,000 F1: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 17, 2023. F2: The stock options were issued to the Reporting Person on August 17,2023, pursuant to a grant under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated. The award vested in full on August 17,2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 17, 2023.
F2: The stock options were issued to the Reporting Person on August 17,2023, pursuant to a grant under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated. The award vested in full on August 17,2023.
Telomir Pharmaceuticals, Inc.
Report date February 08, 2024 · Filed February 08, 2024
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2023 Filed Aug 21, 2023 22:00 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantStock Options · Derivative | 10,000 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001493152-23-029734 · ownership.xml · derivative · entry 1 Nicholoudis Christos · CIK 0001984816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-08-17 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 17, 2023. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on August 17,2023, pursuant to a grant under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated. The award vested in full on August 17,2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.